1. Home
  2. KNRX vs CTSO Comparison

KNRX vs CTSO Comparison

Compare KNRX & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNRX

KNOREX LTD. Class A Ordinary Shares

N/A

Current Price

$1.54

Market Cap

50.5M

Sector

Technology

ML Signal

N/A

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.68

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNRX
CTSO
Founded
2009
1997
Country
Singapore
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.5M
45.9M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
KNRX
CTSO
Price
$1.54
$0.68
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
17.4K
124.7K
Earning Date
01-28-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,820,365.00
$36,979,520.00
Revenue This Year
N/A
$7.26
Revenue Next Year
N/A
$9.78
P/E Ratio
N/A
N/A
Revenue Growth
24.00
23.89
52 Week Low
$1.25
$0.60
52 Week High
$4.00
$1.61

Technical Indicators

Market Signals
Indicator
KNRX
CTSO
Relative Strength Index (RSI) N/A 46.78
Support Level N/A $0.61
Resistance Level N/A $0.77
Average True Range (ATR) 0.00 0.06
MACD 0.00 0.00
Stochastic Oscillator 0.00 48.19

Price Performance

Historical Comparison
KNRX
CTSO

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: